Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thioridazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioridazine SCHEMBL9566 | 1.00 | PIM1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL380206 | 1.00 | PIM1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL12434241 | 1.00 | PIM1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL29384252 | 1.00 | PIM1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL29387384 | 0.99 | TDP1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL41430 | 0.99 | TDP1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL8006297 | 0.99 | TDP1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL30827481 | 0.99 | TDP1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL56533 | 0.98 | PIM1 (0.96) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL28133267 | 0.94 | CYP2D6 (0.89) | PIM1CYP2D6DRD2CYP1A2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048181-A1 | ANTIMICROBIAL POLYCARBONATE COATINGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3777977-B1 | ANTIMICROBIAL CATHETERS | UNIV TEXAS (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20230405191-A1 | ANTIMICROBIAL CATHETERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-21 | — | — | US | disclosed |
| US-11738119-B2 | Antimicrobial catheters | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023128464-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING CARNITINE ACYLCARNITINE CARRIER INHIBITOR AND PEROXISOMAL BETA OXIDATION INHIBITOR | 주식회사 뉴캔서큐어바이오 | 2023-07-06 | — | — | WO | disclosed |
| US-20210060213-A1 | ANTIMICROBIAL CATHETERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-04 | — | — | US | disclosed |
| EP-3777977-A1 | ANTIMICROBIAL CATHETERS | Board of Regents, The University of Texas System (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10888568-B2 | Pharmaceutical composition for treatment of cancer using phenothiazine | NATIONAL YANG MING UNIVERSITY (TW) | 2021-01-12 | — | — | US | disclosed |
| US-10744232-B2 | Antimicrobial catheters | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190070191-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER USING PHENOTHIAZINE | NATIONAL YANG-MING UNIVERSITY (TW) | 2019-03-07 | — | — | US | disclosed |
| US-20140350081-A1 | INSECT G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME | US ARMY, SECRETARY OF THE ARMY | 2014-11-27 | — | — | US | disclosed |
| US-8809299-B2 | Combination therapy for the treatment of cancer | MCMASTER UNIVERSITY (CA) | 2014-08-19 | — | — | US | disclosed |
| US-20130331381-A1 | Treatment of Cancer WIth Dopamine Receptor Antagonists | MCMASTER UNIVERSITY (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130261074-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MCMASTER UNIVERSITY (CA) | 2013-10-03 | — | — | US | disclosed |
| WO-2013143000-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MCMASTER UNIVERSITY (CA) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013126993-A1 | SCREENING ASSAYS FOR IDENTIFYING AND VALIDATING AGENTS THAT TARGET CANCER STEM CELLS | MCMASTER UNIVERSITY (CA) | 2013-09-06 | — | — | WO | disclosed |
| US-20130065887-A1 | Treatment of Cancer with Dopamine Receptor Antagonists | MCMASTER UNIVERSITY (CA) | 2013-03-14 | — | — | US | disclosed |
| US-20120309704-A1 | COMPOSITIONS FOR TREATMENT OF CHEMORESISTANT AND/OR POTENTIALLY CHEMORESISTANT LEUKAEMIAS | NOI PER VOI ONLUS (IT) | 2012-12-06 | — | — | US | disclosed |
| WO-2012163990-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS TREATED WITH NEUROLEPTIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | WO | disclosed |
| US-20110269777-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA USING ANTIPSYCHOTIC COMBINATION THERAPY | MEDIVATION NEUROLOGY, INC. | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350081-A1 | INSECT G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME | DDT, ADRA2C, MCHR1 | DRD2 6/4885DRD3 15/4885HTR2A 56/4885 |
| US-10744232-B2 | Antimicrobial catheters | PARG, GMNN, AMPD2 | DRD2 125/4885DRD3 452/4885HTR2A 2059/4885 |
| US-20230405191-A1 | ANTIMICROBIAL CATHETERS | PARG, GMNN, AMPD2 | DRD2 125/4885DRD3 452/4885HTR2A 2059/4885 |
| US-20260048181-A1 | ANTIMICROBIAL POLYCARBONATE COATINGS | TET2, TET3, DEPTOR | DRD2 31/4885DRD3 37/4885HTR2A 2466/4885 |
| US-20210060213-A1 | ANTIMICROBIAL CATHETERS | PARG, GMNN, AMPD2 | DRD2 125/4885DRD3 452/4885HTR2A 2059/4885 |
| US-11738119-B2 | Antimicrobial catheters | PARG, GMNN, AMPD2 | DRD2 125/4885DRD3 452/4885HTR2A 2059/4885 |
| US-20190070191-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER USING PHENOTHIAZINE | KRAS, NRAS, TP53 | DRD2 1109/4885DRD3 2740/4885HTR2A 488/4885 |
| US-20110269777-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA USING ANTIPSYCHOTIC COMBINATION THERAPY | SLC6A3, DBH, HTR3B | DRD2 18/4885DRD3 26/4885HTR2A 120/4885 |
| US-10888568-B2 | Pharmaceutical composition for treatment of cancer using phenothiazine | KRAS, NRAS, TP53 | DRD2 1109/4885DRD3 2740/4885HTR2A 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.